# Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

> **NCT00933335** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 38 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **BIOLOGICAL:** Tositumomab and Iodine I 131 Tositumomab

## Key facts

- **NCT ID:** NCT00933335
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-08
- **Primary completion:** 2009-12
- **Final completion:** 2010-08
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00933335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00933335, "Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00933335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*